Edwards Lifesciences beats quarterly estimates on robust demand for artificial heart valves

Edwards Lifesciences beat Wall Street first-quarter estimates, helped by robust demand for its artificial valves used in complex cardiac procedures. The earnings beat drove the stock up more than 4% in extended trading, signaling continued strength in its core heart-valve franchise.

Analysis

Edwards Lifesciences beat Wall Street first-quarter estimates, helped by robust demand for its artificial valves used in complex cardiac procedures. The earnings beat drove the stock up more than 4% in extended trading, signaling continued strength in its core heart-valve franchise.